Errol M. Rudman’s Esperion Therapeutics ESPR Stock Holding History

Errol M. Rudman’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-50,000	Closed	-$1.96M	–	53
2018 Q2	$1.96M	Buy	+50,000	New	+$2.53M	0.91%	31

Other funds holding ESPR

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Errol M. Rudman's ESPR Position: Q3 2018 in Review

Errol M. Rudman sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 50,000 shares — an estimated $1.96M sold.

Errol M. Rudman first reported a position in ESPR in Q2 2018 and held it in 1 quarter. The position peaked at $1.96M in Q2 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

Errol M. Rudman reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
Errol M. Rudman sold 50,000 Esperion Therapeutics shares in Q3 2018, an estimated $1.96M.
Errol M. Rudman first reported a position in Esperion Therapeutics in Q2 2018 and held it in 1 quarter.
Errol M. Rudman's Esperion Therapeutics position peaked at $1.96M in Q2 2018.
155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Errol M. Rudman's 13F filing for Q3 2018, filed 14 Nov 2018.